| oral only | RA (D2) | RA (D2, 5-HT2) | RA (D2, 5-HT2, NE alpha-2) | RpA (D2, 5-HT1A) and RA (5-HT2A) | p-value | |
| N | 51 | 52 | 2 | 23 | 2 | |
| Male | 31 (61%) | 36 (71%) | 2 (100%) | 11 (48%) | 1 (50%) | 0.29 |
| Age, mean (SD) | 46.5 (13) | 48.6 (13.8) | 41 (1.4) | 45.7 (10) | 43.5 (30.4) | 0.80 |
| Duration of Illness, mean (SD) | 8.9 (3.1) | 9.1 (2.7) | 11 (0) | 7.2 (3.6) | 6.5 (6.4) | 0.074 |
| Antipsychotics (more than 1) | 21 (41%) | 47 (90%) | 2 (100%) | 23 (100%) | 2 (100%) | <0.001 |
| Oral antipsychotics(more than one) | 21 (41%) | 26 (50%) | 1 (50%) | 11 (48%) | 2 (100%) | 0.53 |
| RA (D2) | 8 (16%) | 36 (69%) | 1 (50%) | 3 (13%) | 0 (0%) | <0.001 |
| RA (D2, 5-HT2) | 24 (47%) | 22 (42%) | 1 (50%) | 8 (35%) | 0 (0%) | 0.64 |
| RA (D2, 5-HT2, NE alpha-2) | 24 (47%) | 24 (46%) | 0 (0%) | 19 (83%) | 2 (100%) | 0.008 |
| RpA (D2, 5-HT1A) and RA (5-HT2A) | 7 (14%) | 4 (8%) | 0 (0%) | 3 (13%) | 2 (100%) | 0.004 |
| RA (D2, 5-HT2) and reuptake inhibitor (NET) | 6 (12%) | 16 (31%) | 1 (50%) | 5 (22%) | 1 (50%) | 0.13 |
| Mood stabilizers, mean (SD) | 0.3 (0.5) | 0.2 (0.5) | 0 (0) | 0.3 (0.4) | 0 (0) | 0.88 |
| Antidepressants, mean (SD) | 0.6 (0.8) | 0.4 (0.7) | 0 (0) | 0.7 (0.8) | 3 (0) | <0.001 |
| Anxiolytics, mean (SD) | 0.7 (0.8) | 0.6 (0.8) | 0 (0) | 1.3 (1.2) | 1 (0) | 0.010 |
| Hypnotics, mean (SD) | 0.2 (0.5) | 0.2 (0.4) | 0 (0) | 0.1 (0.3) | 0 (0) | 0.95 |